LNTH ▼ -0.7% - Lantheus Holdings, Inc. $LNTH - Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs Lantheus Holdings fell 0.7% today following the company's announcement of final FDA approval for BRAVNETSA, a generic radiopharmaceutical bioequivalent and therapeutically equivalent to the branded competitor LUTATHERA for treating neuroendocrine tumors. While the approval represents a significant regulatory milestone for Lantheus, the modest decline may reflect investor concerns about pricing pressure and market competition in the radiopharmaceutical space now that a bioequivalent alternative has been formally cleared. 22-SEP-2026 08:00 AM ET